Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 27;26(1):145.
doi: 10.3390/ijms26010145.

Dysregulated Signaling Pathways in Canine Mammary Tumor and Human Triple Negative Breast Cancer: Advances and Potential Therapeutic Targets

Chen Mei  1 , Ying Liu  1 , Zhenyi Liu  1 , Yan Zhi  1 , Zhaoling Jiang  1 , Xueze Lyu  2 , Hongjun Wang  1
Affiliations
Review

Dysregulated Signaling Pathways in Canine Mammary Tumor and Human Triple Negative Breast Cancer: Advances and Potential Therapeutic Targets

Chen Mei et al. Int J Mol Sci. .

Abstract

In 2022, human breast cancer (HBC) and canine mammary tumors (CMTs) remained the most prevalent malignant tumors worldwide, with high recurrence and lethality rates, posing a significant threat to human and dog health. The development of breast cancer involves multiple signaling pathways, highlighting the need for effective inhibitory drugs that target key proteins in these pathways. This article reviews the dysregulation of the EGFR, PI3K/AKT/mTOR, Hippo, pyroptosis, and PD-1/PD-L1 signaling pathways in HBC and CMT, as well as the corresponding drugs used to inhibit tumor growth, with the aim of providing theoretical support for the development of more efficient drugs.

Keywords: canine mammary tumor; drug targets; human breast cancer; signaling pathways.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
EGFR signaling pathway inhibitors and therapeutic monoclonal antibodies.
Figure 2
Figure 2
PI3K-AKT-mTOR signaling pathway inhibitors in HBC and CMT.
Figure 3
Figure 3
Antibody–drug conjugates for the treatment of mammary cancer.
See this image and copyright information in PMC

References

    1. Fernandez-Rodriguez E.J., Taboada-Taboada R., Garcia-Martin A., Sanchez-Gomez C., Saez-Gutierrez S., Rihuete-Galve M.I., Fonseca-Sánchez E. Study on the additional financial burden of breast cancer disease on cancer patients and their families. Financial toxicity in cancer. Front. Public Health. 2024;12:1324334. doi: 10.3389/fpubh.2024.1324334. - DOI - PMC - PubMed
    1. Escala-Garcia M., Morra A., Canisius S., Chang-Claude J., Kar S., Zheng W., Bojesen S.E., Easton D., Pharoah P.D.P., Schmidt M.K. Breast cancer risk factors and their effects on survival: A Mendelian randomisation study. BMC Med. 2020;18:327. doi: 10.1186/s12916-020-01797-2. - DOI - PMC - PubMed
    1. Cordeiro Y.G., Mulder L.M., van Zeijl R.J.M., Paskoski L.B., van Veelen P., de Ru A., Strefezzi R.F., Heijs B., Fukumasu H. Proteomic Analysis Identifies FNDC1, A1BG, and Antigen Processing Proteins Associated with Tumor Heterogeneity and Malignancy in a Canine Model of Breast Cancer. Cancers. 2021;13:5901. doi: 10.3390/cancers13235901. - DOI - PMC - PubMed
    1. Varney D., O’Neill D., O’Neill M., Church D., Stell A., Beck S., Smalley M.J., Brodbelt D. Epidemiology of mammary tumors in bitches under veterinary care in the UK in 2016. Vet. Rec. 2023;193:e3054. doi: 10.1002/vetr.3054. - DOI - PubMed
    1. Nosalova N., Huniadi M., Horňáková Ľ., Valenčáková A., Horňák S., Nagoos K., Vozar J., Cizkova D. Canine Mammary Tumors: Classification, Biomarkers, Traditional and Personalized Therapies. Int. J. Mol. Sci. 2024;25:2891. doi: 10.3390/ijms25052891. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources